Why This MicroCap Is Catching Mayo Clinic’s Attention | Telo Genomics (TSXV: TELO)

In this conversation, Keir Reynolds interviews Guido Baechler, Executive Chairman of Telo Genomics Corp. (TSXV: TELO; OTCQB: TDSGF), discussing the company's innovative approach to genomics and diagnostics, particularly focusing on telomeres and their potential implications for cancer and other disease diagnosis and treatment...and why this microcap is catching the Mayo Clinic’s attention.

Baechler shares insights into Telo's technology, its applications in various diseases, the process of commercialization, and the competitive landscape. He emphasizes the importance of validation and partnerships in advancing their products and highlights the potential market impact of their diagnostic tests.

About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit https://www.telodx.com/

Chapters:

00:00 Introduction to Telo Genomics and Guido Bakler
03:47 Understanding Telo Genomics' Technology and Applications
08:11 Patents, Certifications, and Clinical Trials
15:02 Commercialization Pathways and Market Potential
22:25 Competitive Landscape and Unique Selling Proposition
32:37 Focus Areas and Future Developments
39:19 Vision for Success and Investor Insights


About Vested One Media:
Vested One Media Inc., owner and host of the TokStocks Podcast, is a financial media company that connects retail investors with market commentary, usually privy to institutions, such as CEO interviews and insights into the markets, sectors and deal flow that could deliver massive potential gains.

We aren’t just another financial media company producing long winded fluffy, always positive content for people who like to see themselves on camera. We are different - we get straight to the point and have a no BS policy. Don’t come on our show if you can’t speak the truth.

Interested in pitching your Company to our network of global investors? Reach out at [email protected] or visit us online at: https://tokstocks.com

Disclaimer:
We are NOT licensed financial advisors. Instead, we operate as a media and technology entity. Our content serves informational purposes only and should NOT be construed as an endorsement or investment recommendation. Some companies featured in our YouTube content and events may compensate us. Additionally, we might hold stock in the companies we discuss. Our investment strategy may involve buying shares with the intention of selling them at a profit. We reserve the right to buy or sell shares in any featured company without prior notice or updates. It's imperative to consult with a qualified financial advisor before making any investment decisions.

We have NOT be paid or compensated for this interview and are not receiving compensation of any kind from Telo Genomics Corp. (TSXV: TELO; OTCQB: TDSGF) but we ARE shareholders. We reserve the right to buy or sell shares in any featured company without prior notice or updates.

#microcapstocks #tsxv #investing #ceo #podcast #mayoclinic #genomics #canada #biotech #biotechstocks #biotech #news #trading #smallcapstocks #diagnostics #cancer #alzheimer #prostatecancer